What is HC Wainwright’s Forecast for IN8bio FY2025 Earnings?

IN8bio, Inc. (NASDAQ:INAB) – Investment analysts at HC Wainwright lifted their FY2025 earnings per share (EPS) estimates for shares of IN8bio in a research report issued to clients and investors on Wednesday, January 14th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($0.66) for the year, up from their previous estimate of ($5.71). The consensus estimate for IN8bio’s current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for IN8bio’s Q4 2025 earnings at ($0.18) EPS, Q1 2026 earnings at ($0.21) EPS, Q2 2026 earnings at ($0.25) EPS, Q3 2026 earnings at ($0.29) EPS, Q4 2026 earnings at ($0.33) EPS, FY2026 earnings at ($1.09) EPS, FY2027 earnings at ($0.95) EPS, FY2028 earnings at ($0.25) EPS, FY2029 earnings at $0.25 EPS and FY2030 earnings at $0.62 EPS.

A number of other brokerages have also weighed in on INAB. Zacks Research upgraded shares of IN8bio from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 14th. Weiss Ratings reissued a “sell (e+)” rating on shares of IN8bio in a report on Wednesday, October 8th. Finally, Mizuho set a $4.00 target price on IN8bio in a report on Monday, October 13th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, IN8bio has an average rating of “Hold” and a consensus price target of $92.00.

IN8bio Trading Up 11.6%

Shares of IN8bio stock opened at $2.59 on Friday. The firm’s 50 day moving average is $1.92 and its 200 day moving average is $2.08. The firm has a market capitalization of $10.93 million, a PE ratio of -0.47 and a beta of -0.01. IN8bio has a 1 year low of $1.17 and a 1 year high of $12.53.

IN8bio (NASDAQ:INAB) last released its earnings results on Thursday, November 6th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.35.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Stonepine Capital Management LLC bought a new stake in IN8bio during the 2nd quarter worth approximately $172,000. Two Sigma Investments LP purchased a new stake in IN8bio in the 3rd quarter valued at $107,000. Finally, Citadel Advisors LLC bought a new position in IN8bio during the 3rd quarter valued at $54,000. Institutional investors and hedge funds own 92.05% of the company’s stock.

IN8bio News Roundup

Here are the key news stories impacting IN8bio this week:

• Positive Sentiment: HC Wainwright raised near-term quarterly EPS forecasts substantially — Q1–Q4 2026 estimates were moved from roughly ($1.20)/($1.50) per quarter to about ($0.21), ($0.25), ($0.29) and ($0.33) respectively, implying materially lower expected losses in 2026 versus the firm’s prior views. HC Wainwright raises near-term EPS estimates
• Positive Sentiment: Annual estimates were also upgraded: FY2025 EPS was revised to ($0.66) and FY2026 to ($1.09) from much larger prior negatives (HC previously forecast FY2026 around ($5.71)), signaling the analyst now expects significantly less downside than before. HC Wainwright upgrades FY2025–FY2026 forecasts
• Positive Sentiment: HC Wainwright laid out a multi-year path to profitability, forecasting FY2029 EPS of $0.25 and FY2030 EPS of $0.62 — a signal that the analyst expects long-term commercialization or margin improvement that could materially change IN8bio’s earnings profile. HC Wainwright projects FY2029–FY2030 profitability
• Neutral Sentiment: Despite upgrades, HC’s FY2026 forecast (-$1.09) remains below the consensus full-year estimate of ($0.56), so analyst views are improving but not fully aligned with market consensus; timing and execution risk remain. Comparison to consensus estimates
• Negative Sentiment: The company is still forecast to be loss-making through the mid-2020s under HC’s model, and its small market cap and historical volatility mean upgrades can spark short-term moves but don’t remove execution, clinical and financing risk. Investors should treat the revisions as improving optimism rather than proof of sustained profitability. Risk and context

About IN8bio

IN8bio, Inc (NASDAQ: INAB) is a clinical-stage biotechnology company focused on the development of novel immunotherapies for the treatment of cancer and neurodegenerative disorders. The company leverages insights into the body’s innate and adaptive immune systems to engineer cell-based products designed to target solid tumors, brain injuries and cognitive decline.

IN8bio’s pipeline is built on two proprietary platforms. The ENACT™ platform centers on allogeneic gamma delta T cell therapies aimed at solid tumors, with lead candidates advancing through early-stage clinical trials in glioblastoma and other oncology indications.